Rapt Therapeutics Stock Performance
| RAPT Stock | USD 57.75 0.07 0.12% |
RAPT Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The firm holds a Beta of 2.22, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RAPT Therapeutics will likely underperform. Use RAPT Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on RAPT Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in RAPT Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, RAPT Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.12 | Five Day Return 0.14 | Year To Date Return 81.32 | Ten Year Return (44.47) | All Time Return (44.47) |
Last Split Factor 1:8 | Last Split Date 2025-06-17 |
1 | Foresite Capital Management VI LLC Has 12.50 Million Stake in Rapt Therapeutics RAPT | 11/25/2025 |
2 | RAPT Therapeutics Is Up 8.0 percent After Index Additions And Trial Progress News Has The Bull Case Changed - Sahm | 12/24/2025 |
3 | Piper Sandler initiates coverage on Rapt Therapeutics stock with Overweight rating - Investing.com | 01/09/2026 |
4 | Rapt Therapeutics Short Interest Update - MarketBeat | 01/15/2026 |
5 | RAPT Therapeutics stock surges 63 percent in pre-market trade on Nasdaq after GSKs 2.2 billion acquisition deal | 01/20/2026 |
6 | Assessing RAPT Therapeutics Valuation After A Sharp Share Price Surge | 01/23/2026 |
7 | Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights | 01/29/2026 |
8 | BRODSKY SMITH SHAREHOLDER UPDATE Notifying Investors of the Following Investigations RAPT Therapeutics, Inc. , Penumbra, Inc. , Calavo Growers, Inc. , FONAR Cor... | 02/02/2026 |
| Begin Period Cash Flow | 47.5 M | |
| Total Cashflows From Investing Activities | 52.7 M |
RAPT Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,904 in RAPT Therapeutics on November 6, 2025 and sell it today you would earn a total of 2,871 from holding RAPT Therapeutics or generate 98.86% return on investment over 90 days. RAPT Therapeutics is currently generating 1.4451% in daily expected returns and assumes 9.0851% risk (volatility on return distribution) over the 90 days horizon. In different words, 81% of stocks are less volatile than RAPT, and 71% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RAPT Therapeutics Target Price Odds to finish over Current Price
The tendency of RAPT Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 57.75 | 90 days | 57.75 | about 1.15 |
Based on a normal probability distribution, the odds of RAPT Therapeutics to move above the current price in 90 days from now is about 1.15 (This RAPT Therapeutics probability density function shows the probability of RAPT Stock to fall within a particular range of prices over 90 days) .
RAPT Therapeutics Price Density |
| Price |
Predictive Modules for RAPT Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as RAPT Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.RAPT Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. RAPT Therapeutics is not an exception. The market had few large corrections towards the RAPT Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold RAPT Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of RAPT Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.17 | |
β | Beta against Dow Jones | 2.22 | |
σ | Overall volatility | 9.61 | |
Ir | Information ratio | 0.14 |
RAPT Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of RAPT Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for RAPT Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| RAPT Therapeutics is way too risky over 90 days horizon | |
| RAPT Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (129.87 M) with profit before overhead, payroll, taxes, and interest of 1.53 M. | |
| RAPT Therapeutics currently holds about 207.34 M in cash with (83.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99. | |
| RAPT Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: BRODSKY SMITH SHAREHOLDER UPDATE Notifying Investors of the Following Investigations RAPT Therapeutics, Inc. , Penumbra, Inc. , Calavo Growers, Inc. , FONAR Corporation |
RAPT Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of RAPT Stock often depends not only on the future outlook of the current and potential RAPT Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. RAPT Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.1 M | |
| Cash And Short Term Investments | 231.1 M |
RAPT Therapeutics Fundamentals Growth
RAPT Stock prices reflect investors' perceptions of the future prospects and financial health of RAPT Therapeutics, and RAPT Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RAPT Stock performance.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 28.96 M | ||||
| Price To Book | 10.98 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M | ||||
| EBITDA | (134.9 M) | ||||
| Net Income | (129.87 M) | ||||
| Cash And Equivalents | 207.34 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 4.49 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 15.97 X | ||||
| Book Value Per Share | 9.02 X | ||||
| Cash Flow From Operations | (83.3 M) | ||||
| Earnings Per Share | (11.66) X | ||||
| Market Capitalization | 1.67 B | ||||
| Total Asset | 240.32 M | ||||
| Retained Earnings | (614.55 M) | ||||
| Working Capital | 186.88 M | ||||
| Current Asset | 17 K | ||||
| Current Liabilities | 167 K | ||||
About RAPT Therapeutics Performance
Assessing RAPT Therapeutics' fundamental ratios provides investors with valuable insights into RAPT Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RAPT Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.79) | (0.83) |
Things to note about RAPT Therapeutics performance evaluation
Checking the ongoing alerts about RAPT Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RAPT Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RAPT Therapeutics is way too risky over 90 days horizon | |
| RAPT Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (129.87 M) with profit before overhead, payroll, taxes, and interest of 1.53 M. | |
| RAPT Therapeutics currently holds about 207.34 M in cash with (83.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99. | |
| RAPT Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: BRODSKY SMITH SHAREHOLDER UPDATE Notifying Investors of the Following Investigations RAPT Therapeutics, Inc. , Penumbra, Inc. , Calavo Growers, Inc. , FONAR Corporation |
- Analyzing RAPT Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RAPT Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining RAPT Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RAPT Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RAPT Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RAPT Therapeutics' stock. These opinions can provide insight into RAPT Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.